Biotech Values

[DaubersUP]

Prurisol is very exciting to me. Psoriasis is an 8 billion dollar market and biologics are brutal, many with black box warnings if not all.

This phase 2b is an apples to apples comparison using the PASI scale. Phase 2a used the IGA scale where the 200 mg arm showed promise. So in the phase 2b the company jumped the arms to 300 and 400mg.

We know an oral drug called Otezla pulled in about 1.25 billion, and that drug set the bar at 33% PASI 75

Prurisol works quicker and has less side effects.

It also comes with the fda 505 b 2 designation. That means a quicker phase 3 and it is eligible for additional years of exclusivity. The company owns it outright and has strong patent protection. The manufacturing cost is minimal as well.

We should see data within the next 2 months.

It’s time this company moves forward and loses the childish audience and penny flippers. The board is brutal on iHub for that company.